---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009260"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:37:51.479424+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Virios Therapeutics reports Q1 2023 net loss of $1.5M; FDA amenable to IMC-1 Phase 3 proposal

## Summary
- Net loss $1.5M ($0.08 per share) vs $4.0M ($0.48) in Q1 2022; R&D expenses fell to $0.5M from $2.8M.
- Cash $5.3M as of March 31, 2023; company expects runway into Q2 2024, but IMC-1 trials need additional funding.
- FDA amenable to Phase 3 program for IMC-1 (famciclovir/celecoxib) for fibromyalgia, pending review of chronic toxicology reports submitted in May 2023.
- Top-line results from exploratory Long-COVID study (valacyclovir/celecoxib) expected in June 2023.

## SEC filing metadata
- accession: 0001558370-23-009260
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/0001558370-23-009260-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/tmb-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009260
- JSON: https://secwatch.observer/filing/0001558370-23-009260.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009260.txt

## Key facts
- Earnings Releases
  Dogwood Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share, EPS $0.08 basic and diluted net loss per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share
  - EPS: $0.08 basic and diluted net loss per share
  - Result: reported results
  source text: Net loss for the first quarter of 2023 was $1.5 million, or $0.08 basic and diluted net loss per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818844/000155837023009260/0001558370-23-009260-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.